LucasBio is devoted to constantly moving
forward to develop new biomedical drugs for incurable diseases.
2025.07
- Clinical study results on the complete recovery of severe COVID-19 published in Clinical Infectious Diseases, the official journal of the Infectious Diseases Society of America (IDSA)
2025.05
- Approval for advanced regenerative medicine high-risk clinical study: "A prospective clinical study to evaluate the safety and efficacy of multi-virus-specific T-cell therapy for the treatment of reactivated latent viral infections following allogeneic hematopoietic stem cell transplantation in pediatric and adolescent patients" (Approval No. R-3-0017)
2025.04
- IND approval of "A single-center, open-label, Phase 1/2 clinical trial to evaluate the safety and efficacy of LB-DTK-MV administration after allogeneic hematopoietic stem cell transplantation" (No. 102599)
- Selected as a joint innovation R&D support project between a university research institute and a startup: Development of a hepatitis B virus-specific memory T cell therapy (LB-DTK-HBV) for the functional cure of chronic hepatitis B patients
- Selected as a research project for the R&D Program for Overcoming Pediatric Diseases, supported by the Korea Health Industry Development Institute (KHIDI)
"Development of a BK virus-specific memory T-cell therapy (LB-DTK-BKV) for the treatment of intractable BK virus hemorrhagic cystitis following allogeneic hematopoietic stem cell transplantation in pediatric and adolescent patients."
2025.03
- PCT application for a "High-purity, high-potency cell therapy product containing decidua-derived stromal cells" (PCT/KR2025/002985)
2024.12
- Domestic Patent Application for "Improving the Cryopreservation and Infusion Stability and Efficacy of DSC-Based Cell Therapy Products Containing Heparin" (10-2024-0178554)
2024.09
- Ministry of Food and Drug Safety Clinical Trial Approval: No. 102261
'Single-center, open-label, phase 1 clinical trial to evaluate the safety, tolerability, and efficacy of a single dose of LB-DTK-COV19 in patients with severe COVID-19'
2024.07
- Approval of designation by Korean FDA as Good Clinical Laboratory Practice Central Lab
2024.03
- Domestic Patent Application for "Decidua-Derived Stromal Cell Population and Its Uses" (10-2024-0032215)
- "Domestic Patent Application for "High-Purity, High-Potency Cell Therapy Product Containing Decidua-Derived Stromal Cells" (10-2024-0032214)
2024.02
- First successful recovery in Korea of a patient with prolonged severe COVID-19 infection using an autologous SARS-CoV-2-specific T cell therapy
2023.05
- Selected as a research project for the Korea Health Industry Development Institute infectious disease prevention and treatment technology development project
'Research on the development of SARS coronavirus-2 antigen-specific T cell therapy for the treatment of new and variant COVID-19'
2023.04
- Selected as a research project for the regenerative medicine linked technology development project by the pan-governmental regenerative medicine technology development project group
''Safety, effectiveness evaluation and commercialization research of placental decidua stromal cell therapy to overcome inflammatory bowel disease'
2023.02
- Approval for advanced regenerative medicine medium-risk clinical study: autologous COVID-19-specific T cells
'Clinical study to evaluate the safety and effectiveness of autologous COVID-19 antigen-specific T cell therapy for patients infected with SARS-Coronavirus-2 for a long period of time'
2023.01
- Selected as a research project for the National Research Foundation of Korea market-linked biotechnology development project
'Research to establish the concept of placental decidua-derived stromal cells and secure treatment for intractable complications that occur after allogeneic hematopoietic stem cell transplantation'
2022.06
- Selected as a research project for the Korea Health Industry Development Institute’s Regenerative Medicine Clinical Research Foundation Creation Project
'Establishment of a hospital-based cell therapy consignment development and production system'
2021.12
- Approved for advanced regenerative medicine medium-risk clinical study: autologous cytokine-induced killer cells
'Researcher-led clinical study to evaluate the safety of cytokine-induced killer cell administration in the early stages of transplantation in autologous hematopoietic stem cell transplant patients'
2020.10
- Received venture certificate - Korea SME's and Startups Agency
2020.07
- Established Lucasbio's R&D Lab
2020.03
- Japanese Patent Registration: Method for inducing and proliferating viral antigen-specific T cells
(No. 2018-521069)
2019.07
- Establishment of LucasBio Co., Ltd.
2018.06
- Korean Patent Registration: Method for inducing and proliferating viral antigen-specific T cells
(No. 10-1867942)
